Neurocrine Biosciences Inc. (NBIX) Forecasted to Post Q3 2016 Earnings of ($0.53) Per Share
Neurocrine Biosciences Inc. (NASDAQ:NBIX) – Research analysts at Leerink Swann issued their Q3 2016 earnings per share estimates for Neurocrine Biosciences in a research report issued on Tuesday. Leerink Swann analyst P. Matteis anticipates that the firm will earn ($0.53) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $70.00 target price on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2016 earnings at ($0.65) EPS, FY2016 earnings at ($1.86) EPS, FY2017 earnings at ($2.17) EPS and FY2018 earnings at ($1.39) EPS.
A number of other equities analysts have also recently commented on NBIX. Cowen and Company reaffirmed a “buy” rating and set a $65.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $96.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, September 22nd. HC Wainwright began coverage on shares of Neurocrine Biosciences in a research report on Wednesday, June 29th. They set a “buy” rating and a $80.00 price objective for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, September 23rd. Finally, TheStreet cut shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 14th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $65.50.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 46.98 on Thursday. The company’s market cap is $4.08 billion. The firm’s 50-day moving average is $50.95 and its 200-day moving average is $47.42. Neurocrine Biosciences has a one year low of $31.25 and a one year high of $58.46.
In related news, insider Christopher Flint Obrien sold 12,500 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $48.73, for a total value of $609,125.00. Following the completion of the transaction, the insider now owns 55,044 shares of the company’s stock, valued at $2,682,294.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,000 shares of the business’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $50.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now directly owns 9,000 shares of the company’s stock, valued at approximately $450,000. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Mercantile Trust Co. increased its position in Neurocrine Biosciences by 94.9% in the third quarter. First Mercantile Trust Co. now owns 3,897 shares of the company’s stock worth $197,000 after buying an additional 1,897 shares during the period. Stephens Inc. AR bought a new position in Neurocrine Biosciences during the second quarter worth approximately $205,000. Massmutual Trust Co. FSB ADV bought a new position in Neurocrine Biosciences during the first quarter worth approximately $189,000. Adams Diversified Equity Fund Inc. bought a new position in Neurocrine Biosciences during the second quarter worth approximately $223,000. Finally, BlueMountain Capital Management LLC bought a new position in Neurocrine Biosciences during the second quarter worth approximately $268,000. 96.70% of the stock is owned by institutional investors and hedge funds.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.
Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.